Vivione Biosciences Enters Into CRADA with FDA to Expand Capability of RAPID-B™ Diagnostic System

Vivione Biosciences Corporation (TSXV:VBI) entered into a new three-year Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration’s (FDA) National Center for Toxicological Research (NCTR) to expand the capability of the Company’s RAPID-B™ diagnostic system.

As quoted in the press release:

The Vivione RAPID-B™ system is a revolutionary high-performance diagnostic system for detecting bacterial pathogens. Unlike other systems that look at a gross response of an entire sample to provide information, the RAPID-B™ system looks individually at each bacterium’s physical properties (including size, shape, and transparency) and analyzes unique responses to probes and DNA dyes. RAPID-B™ allows the testing of food products in seven hours or less, including sample preparation versus other commercial systems that take up to 48 hours to provide results. Moreover, single shift results are achieved without the need for labor intensive sample preparation steps including centrifugation and immuno-magnetic separation.

Overall the research under the CRADA will strive to expand the utility of RAPID-B™ to a greater variety of locations and contexts, including field settings and clinical venues. According to Moskal, the goal is to design and test new RAPID-B™ assays capable of real-time detection of diverse pathogens directly from the native sample thus reducing the steps associated with typical sample preparations and yielding faster, simpler and cost-effective diagnostic tests.

Vivione Biosciences Corporation President and Chief Science Officer, Ted Moskal, said:

New research contemplated under the CRADA will augment the present RAPID-B™ assays for food safety. We are developing new methods that can rapidly identify the pathogens responsible for disease outbreaks beyond food-borne illnesses.

Click here to read the Vivione Biosciences Corporation (TSXV:VBI) press release